Abstract
Introduction

Laboratory analysis 177
Biochemical analysis Plasma glucose concentration, lipid profile, liver function parameters 178 and HbA1c were measured using a Cobas 8000 modular analyser (Roche diagnostics, USA). 179
Blood glucose concentrations during hyperglycaemic clamp were measured using YSI 2300 180 STAT glucose analyser (YSI U.K Ltd, Fleet, Hampshire, U.K). Serum insulin was measured 181 by ELISA method (Invitrogen, Fisher Scientific Ltd Loughborough, U.K). Non-Esterified 182
Fatty Acids (NEFAs) were measured from plasma by Randox kit on a Biostat BSD 570 183 analyser (Randox laboratories Ltd, London). Intact GIP was measured at the University of 184 Copenhagen, Denmark: the assay is specific for the intact N-terminus of GIP (biologically 185 active peptide) (13). (SAT-TAG) parameters to explore whether the change over the two time points differed9 between GIP and placebo. P value of < 0.05 (two-tailed) was considered to be significant. 213
A Pearson product-moment correlation coefficient was computed to assess the relationship 214 between degree of NEFA reduction and other variables (fasting plasma glucose and AdiposeA linear mixed-effects model was also used to model insulin secretion and NEFA 217 concentrations using three time points (baseline, 120 minutes and 240 minutes). Main effects 218 for the four different groups are included along with a two-way interaction between treatment 219 and group. This allows that the overall effect of GIP infusion in comparison to the placebo 220 infusion can be assessed individually for different groups. Results are expressed in estimated 221 average unit changes in insulin and NEFAs during GIP vs. placebo infusion. 222
223
Results
224
Baseline characteristics (Table 1 ) 225
Patient demographics 226
Twenty three individuals completed the study protocol in four sub-groups: lean (n=6), obese 227 (n=6), obese IGR (n=6) and obese T2DM (n=5). Waist circumference and percentage body 228 fat mass were significantly higher in obese, obese IGR, obese T2DM compared to the lean 229 group. The duration of diabetes in obese T2DM group was 7 ± 5.5 months (mean ± SD), 230 mean HbA1c of 54 ± 8.5 mmol/mol (7.1 ± 0.8 %) and all participants were naive to oral or 231 injectable diabetes medications. 232
233
Baseline biochemistry 234
Plasma glucose and insulin concentrations 235
As expected, mean fasting glucose was higher in obese IGR and obese T2DM groups 236 compared to the two other groups. Fasting insulin and HOMA-IR were significantly higher in 237 obese, obese IGR and obese T2DM groups vs. the lean group. Adipo-IR was significantly 238 higher in obese T2DM group vs. lean and obese groups but not vs. obese IGR group (Table 1)  239 240
Metabolic parameters 241
All subjects in obese IGR and obese T2DM groups had metabolic syndrome based on 242
International Diabetes Federation 2006 criteria (2) with most consequently treated for 243 hypertension and dyslipidemia: ACE inhibitors or angiotensin receptor blockers (three 244 subjects in obese IGR group, five subjects in obese T2DM group), beta-blockers (two obese 245 IGR, 2 obese T2DM) and calcium channel blocker (one obese T2DM). Three subjects in each 246 of the above two groups were on statins. Two subjects in the obese group had metabolic 247 syndrome (one on ACE inhibitors and one a fibrate). [ Table 1 ]. 248 249
Biochemistry changes during infusions 250
Blood glucose. The blood glucose concentrations were maintained at ~8.0 mmol/l during the 251 hyperglycaemic clamp with both GIP and placebo infusions in all four groups ( Figure 1A-D 30.5 ± 4.6, 23.2 ± 2.6 pmol/l with GIP vs. 13.7 ± 2.2, 8.3 ±1.9, 9.7 ± 2.8 pmol/l with 266 placebo, obese (15.2 ± 2.9, 38.8 ± 6.9, 21.8 ± 5.3 pmol/l with GIP vs. 13.0 ± 2, 15 ±3.4, 15.2 267 ± 5pmol/l with placebo), obese IGR (14.2 ± 3.7, 38.2 ± 7, 26.7 ± 4.7 pmol/l with GIP vs. 268 12.2 ± 2.9, 13.5 ± 2.5, 12.8 ±1.6 pmol/l with placebo), obese T2DM (14.2 ± 2, 51.6 ± 7.2, 26 269 ± 7.2 pmol/l with GIP vs. 14.4 ± 2, 23 ± 9.8, 17.8 ± 6.5 pmol/l with placebo). All studies were performed under hyperglycaemic clamp conditions to achieve comparable 403 hyperglycaemia and to mimic post-prandial increases in GIP and insulin. The peak GIP 404 concentrations achieved in our study during GIP infusions were comparable to levels 405 achieved elsewhere (3). We believe the changes in NEFAs and SAT lipid content in our 406 obese T2DM are more likely due to the effect of GIP, particularly in the absence of excess 407 insulin secretion. Reductions in NEFA correlated positively with fasting glucose and 408
Adipo-IR in all the subjects across the four groups suggesting the effects of GIP are more 409 pronounced in hyperglycaemic and insulin resistant states. We recognise that higher ∆NEFA 410 would be expected in subjects with higher fasting NEFA levels however correlation with 411
Adipo-IR was only seen with GIP but not with placebo infusion (Figure 4) . 412
413
Studying four distinct groups (with differing BMI and glucose tolerance) facilitates 414 evaluation of the differential effects of GIP in insulin sensitive and resistant individuals. 415
However, we acknowledge limitations including small group sizes and the degree of obesity: 416 there was limited pilot data in humans prior to initiation of this study and subsequently 417 published human studies on GIP infusion had small number of subjects (3-5). Findings from 418 our study may differ in less severely obese individuals. Lean subjects were younger 419 compared to others and may have increased insulinotropic activity to GIP (30) but there was 420 no significant difference in Insulin AUC between the groups except in obese T2DM. 421
Unrecognised interactions between anti-hypertensive or lipid modifying medication and 422 effects of GIP cannot be excluded. 423
424
In conclusion, we demonstrate that in obese patients with T2DM, acute GIP infusion in a 425 fasting state, during hyperglycaemia, lowers serum NEFA and increases the SAT lipid 426 content despite reduced insulinotropic activity. In lean, obese and obese with IGR, despite the 427 intact insulinotropic response to GIP no lipogenic effect was observed. This anabolic effect of 428 GIP further exacerbates obesity and insulin resistance. In obesity, with consumption of an energy-dense, higher fat diet, there is enhanced insulin 636 secretion (which may help overcome peripheral insulin resistance) and increased lipid 637 deposition (which will further enhance fat storage) (middle figure). In T2DM, the effects of 638 GIP on beta cell are impaired with reduced insulin secretion; the effects on the adipocyte 639 seem to be preserved further promoting lipid deposition (right figure) . 
